The purpose of the study is to explore association patterns between digital outcome assessments from Konectom and MRI measures of brain tissue damage.

Inclusion Criteria:

• Should be enrolled in multiple sclerosis partners advancing technology and health solutions (MS PATHS).
• Participant (or participant's legal representative) has the ability to understand the purpose and risks of the study, to provide signed and dated informed consent, and to authorize the use of confidential health information in accordance with national and local privacy regulations.
• Should have literacy of written language in which the software and Instructions for use are displayed (User Interface [UI], Instructions).

Exclusion Criteria:

• Unable or unwilling to provide informed consent.
• Inability to use a smartphone as per physician's opinion.
• Not owning a Konectom-compatible smartphone.
• Other unspecified reasons that, in the opinion of the Investigator or Biogen, make the participant unsuitable for participation in the sub-study. A participant only needs to complete the assessments deemed necessary by the Investigator.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

The study population includes participants with a diagnosis of MS who are enrolled in MS PATHS.

In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/